Apellis Pharmaceuticals (APLS) Competitors

Apellis Pharmaceuticals (NASDAQ:APLS) and Viatris (NASDAQ:VTRS) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, dividends, analyst recommendations, institutional ownership and earnings.

Which has more risk & volatility, APLS or VTRS?

Apellis Pharmaceuticals has a beta of 0.78, suggesting that its stock price is 22% less volatile than the S&P 500. Comparatively, Viatris has a beta of 0.9, suggesting that its stock price is 10% less volatile than the S&P 500.

Which has higher earnings and valuation, APLS or VTRS?

Apellis Pharmaceuticals has higher earnings, but lower revenue than Viatris. Apellis Pharmaceuticals is trading at a lower price-to-earnings ratio than Viatris, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apellis Pharmaceuticals	$754.65M	4.60	-$197.88M	-$1.82	-15.10
Viatris	$14.74B	0.83	-$634.20M	-$2.90	-3.63

Do analysts rate APLS or VTRS?

Apellis Pharmaceuticals presently has a consensus target price of $34.12, suggesting a potential upside of 24.16%. Viatris has a consensus target price of $10.40, suggesting a potential downside of 1.27%. Given Apellis Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Apellis Pharmaceuticals is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apellis Pharmaceuticals	0 Sell rating(s)	9 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.58
Viatris	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80

Does the media prefer APLS or VTRS?

In the previous week, Apellis Pharmaceuticals had 8 more articles in the media than Viatris. MarketBeat recorded 13 mentions for Apellis Pharmaceuticals and 5 mentions for Viatris. Apellis Pharmaceuticals' average media sentiment score of 1.37 beat Viatris' score of 0.00 indicating that Apellis Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Apellis Pharmaceuticals	11 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Viatris	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do insiders & institutionals hold more shares of APLS or VTRS?

96.3% of Apellis Pharmaceuticals shares are held by institutional investors. Comparatively, 79.9% of Viatris shares are held by institutional investors. 6.5% of Apellis Pharmaceuticals shares are held by company insiders. Comparatively, 0.1% of Viatris shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Is APLS or VTRS more profitable?

Viatris has a net margin of -24.57% compared to Apellis Pharmaceuticals' net margin of -30.24%. Viatris' return on equity of 16.54% beat Apellis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apellis Pharmaceuticals	-30.24%	-116.09%	-26.72%
Viatris	-24.57%	16.54%	7.06%

Summary

Apellis Pharmaceuticals beats Viatris on 11 of the 17 factors compared between the two stocks.